KR20210130774A - 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 - Google Patents

3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 Download PDF

Info

Publication number
KR20210130774A
KR20210130774A KR1020217030409A KR20217030409A KR20210130774A KR 20210130774 A KR20210130774 A KR 20210130774A KR 1020217030409 A KR1020217030409 A KR 1020217030409A KR 20217030409 A KR20217030409 A KR 20217030409A KR 20210130774 A KR20210130774 A KR 20210130774A
Authority
KR
South Korea
Prior art keywords
salt
compound
present disclosure
day
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217030409A
Other languages
English (en)
Korean (ko)
Inventor
가즈히코 요네쿠라
히로시 히라이
가즈아키 마츠오카
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20210130774A publication Critical patent/KR20210130774A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217030409A 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 Ceased KR20210130774A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019035603 2019-02-28
JPJP-P-2019-035603 2019-02-28
JP2019112619 2019-06-18
JPJP-P-2019-112619 2019-06-18
PCT/JP2020/008527 WO2020175704A1 (ja) 2019-02-28 2020-02-28 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法

Publications (1)

Publication Number Publication Date
KR20210130774A true KR20210130774A (ko) 2021-11-01

Family

ID=72239799

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217030409A Ceased KR20210130774A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법
KR1020217030410A Ceased KR20210131387A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217030410A Ceased KR20210131387A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법

Country Status (8)

Country Link
US (2) US20220184082A1 (https=)
EP (2) EP3932425A4 (https=)
JP (6) JPWO2020175697A1 (https=)
KR (2) KR20210130774A (https=)
AU (4) AU2020228514B2 (https=)
MA (2) MA55088A (https=)
TW (2) TW202039507A (https=)
WO (2) WO2020175704A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
AU2020352668A1 (en) * 2019-09-26 2022-03-31 Janssen Pharmaceutica Nv Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2025046272A1 (en) 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Methods of treating cancer using futibatinib and pembrolizumab

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
KR20130108809A (ko) 2012-03-26 2013-10-07 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
JP2016161239A (ja) 2015-03-03 2016-09-05 ダイキン工業株式会社 熱交換器および空気調和機
JP2017150725A (ja) 2016-02-24 2017-08-31 三菱電機株式会社 冷蔵庫

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2657233T3 (da) * 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
WO2015008844A1 (ja) * 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US20170145103A1 (en) * 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
KR20130108809A (ko) 2012-03-26 2013-10-07 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
JP2016161239A (ja) 2015-03-03 2016-09-05 ダイキン工業株式会社 熱交換器および空気調和機
JP2017150725A (ja) 2016-02-24 2017-08-31 三菱電機株式会社 冷蔵庫

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Cancer Res. 70, 2085-2094(2010)
Cell. 168:707-723(2017)
Cellular Physiology and Biochemistry, 33, p.633-645(2014)
frontirs in Immunology, 9, 2018, Article1310. doi:10. 3389/fimmu. 2018. 01310
J. Clin. Oncol. 24, 3664-3671(2006)
JCO Precision Oncology(DOI:10. 1200/P0.18. 00117) July 24, 2018
Mol. Cancer Res. 3, 655-667(2005)
N. Engl. J. Med., 366:2443-2454(2012)
N. Engl. J. Med., 375:819-829(2016)
Nat. Rev. Cancer 10:116-129(2010)
Nat. Rev. Cancer, 12:252-264(2012)
Oncotarget. 8:16052-16074(2017)
Sci. Transl. Med. 9, eaal3604(2017)
The Breast. 37, 126-133(2018)

Also Published As

Publication number Publication date
WO2020175697A1 (ja) 2020-09-03
EP3932425A1 (en) 2022-01-05
TW202039507A (zh) 2020-11-01
EP3932427A1 (en) 2022-01-05
US20220125793A1 (en) 2022-04-28
AU2020228514A1 (en) 2021-10-07
MA55088A (fr) 2022-01-05
JP2025075059A (ja) 2025-05-14
KR20210131387A (ko) 2021-11-02
WO2020175704A1 (ja) 2020-09-03
US20220184082A1 (en) 2022-06-16
JP2023112136A (ja) 2023-08-10
JP2024152860A (ja) 2024-10-25
JPWO2020175704A1 (https=) 2020-09-03
MA55091A (fr) 2022-01-05
TW202045182A (zh) 2020-12-16
EP3932427A4 (en) 2022-12-07
EP3932425A4 (en) 2022-12-07
AU2020228514B2 (en) 2025-02-27
AU2020229714B2 (en) 2025-02-27
JPWO2020175697A1 (https=) 2020-09-03
JP2023096156A (ja) 2023-07-06
AU2020229714A1 (en) 2021-10-07
AU2025203861A1 (en) 2025-06-19
AU2025203865A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
JP2023085370A (ja) 免疫調節剤を併用するがんの治療
KR20210130774A (ko) 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법
JP2020517640A5 (https=)
KR20190137151A (ko) 병용 요법
TW201625270A (zh) 用於治療贅瘤形成的治療組合及方法
KR20230023810A (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr 억제제의 조합
AU2018351007B2 (en) Treatment of ovarian cancer with anti-CD47 and anti-PD-L1
JP2020517629A5 (https=)
KR20190137847A (ko) 항-cd25 항체-약물 접합체와의 병용 요법
Fan et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and combination rationales
CN111629731A (zh) 治疗癌症的组合物和方法
RU2843836C2 (ru) Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и ингибитора иммунной контрольной точки
RU2822064C2 (ru) Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и пембролизумаба
RU2838452C1 (ru) Комбинация антагониста pd-1, ингибитора тирозинкиназы vegfr/fgfr/ret и ингибитора cbp/бета-катенина для лечения рака
TW202517295A (zh) 包含3,5-二取代苯炔基化合物與免疫檢查點抑制藥之癌症治療法
HK40092424A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031A (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
HK40036031B (en) Treatment of ovarian cancer with anti-cd47 and anti-pd-l1

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601